Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
Version v4-EN | Version v2-FR | |
---|---|---|
Language | English | French |
Date Updated | 2021-07-28 | 2021-04-30 |
Drug Identification Number | 02139510 | 02139510 |
Brand name | SODIUM CHLORIDE INJECTION, USP | SODIUM CHLORIDE INJECTION, USP |
Common or Proper name | Sodium Chloride Injection, USP 4 mEq/mL Maxivial® 200 mL | Sodium Chloride Injection, USP 4 mEq/mL Maxivial® 200 mL |
Company Name | FRESENIUS KABI CANADA LTD | FRESENIUS KABI CANADA LTD |
Ingredients | SODIUM CHLORIDE | SODIUM CHLORIDE |
Strength(s) | 234MG | 234MG |
Dosage form(s) | SOLUTION | SOLUTION |
Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
Packaging size | 200 mL | 200 mL |
ATC code | B05XA | B05XA |
ATC description | I.V. SOLUTION ADDITIVES | I.V. SOLUTION ADDITIVES |
Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
Anticipated start date | 2021-05-03 | 2021-05-03 |
Actual start date | 2021-05-03 | 2021-05-03 |
Estimated end date | 2021-08-31 | 2021-07-31 |
Actual end date | ||
Shortage status | Actual shortage | Anticipated shortage |
Tier 3 Status | No | No |
Company comments | Fresenius Kabi Canada Ltd. regrets to advise that due to a production delay we will be extending the current backorder on our Sodium Chloride Injection, USP 4 mEq/mL Maxivial® 200 mL until August 31, 2021. Please note that allocations of our Sodium Chloride Injection, USP 4 mEq/mL Maxivial® 100 mL have been increased to cover the 200mL demand. | Fresenius Kabi Canada Ltd. regrets to advise that due to a production delay, we will be placing our Sodium Chloride Injection, USP 4 mEq/mL Maxivial® 200 mL on reduced allocation. Contract customers will be allocated 75% of their historical average monthly volumes, effective Monday, May 3, 2021. We will also be anticipating a backorder for this product effective June 1, 2021 until July 31, 2021. Please note that allocations of our Sodium Chloride Injection, USP 4 mEq/mL Maxivial® 100 mL have been increased to cover the 200mL demand. |
Health Canada comments |